Recently, a new trial has started: the INDUCE-3 trial is a randomized, double-blind study of GSK3359609 plus pembrolizumab vs placebo plus pembrolizumab for first-line treatment of PD-L1-positive R/M HNSCC. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.